HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pillinger, M. H. Articles by Abramson, S. B. Search for Related Content PubMed PubMed Citation Articles by Pillinger, M. H. Articles by Abramson, S. B.

Cyclooxygenase-2-Derived E Prostaglandins Down-Regulate Matrix Metalloproteinase-1 Expression in Fibroblast-Like Synoviocytes via Inhibition of Extracellular Signal-Regulated Kinase Activation ¹

Michael H. Pillinger^2,*,,, Pamela B. Rosenthal^*,, Sonia N. Tolani^*,, Beth Apsel^*,, Victoria Dinsell^*,, Jeffrey Greenberg^*,,, Edwin S. L. Chan, Paul F. Gomez^*, and Steven B. Abramson^*,

^* Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY 10016; Hospital for Joint Diseases, New York, NY 10003; New York Harbor Healthcare System of the Veterans Administration, New York, NY 10010; and Division of Clinical Pharmacology, New York University School of Medicine, New York, NY 10016

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
We examined the regulation of matrix metalloproteinase (MMP) production by mitogen-activated protein kinases and cyclooxygenases (COXs) in fibroblast-like synoviocytes (FLSCs). IL-1 and TNF- stimulated FLSC extracellular signal-regulated kinase (ERK) activation as well as MMP-1 and -13 release. Pharmacologic inhibitors of ERK inhibited MMP-1, but not MMP-13 expression. Whereas millimolar salicylates inhibited both ERK and MMP-1, nonsalicylate COX and selective COX-2 inhibitors enhanced stimulated MMP-1 release. Addition of exogenous PGE₁ or PGE₂ inhibited MMP-1, reversed the effects of COX inhibitors, and inhibited ERK activation, suggesting that COX-2 activity tonically inhibits MMP-1 production via ERK inhibition by E PGs. Exposure of FLSCs to nonselective COX and selective COX-2 inhibitors in the absence of stimulation resulted in up-regulation of MMP-1 expression in an ERK-dependent manner. Moreover, COX inhibition sufficient to reduce PGE levels increased ERK activity. Our data indicate that: 1) ERK activation mediates MMP-1 but not MMP-13 release from FLSCs, 2) COX-2-derived E PGs inhibit MMP-1 release from FLSCs via inhibition of ERK, and 3) COX inhibitors, by attenuating PGE inhibition of ERK, enhance the release of MMP-1 by FLSC.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
By virtue of their increased numbers in pannus, their close association with cartilage, and their ability to produce and export matrix metalloproteinases (MMPs) such as MMP-1, -3, -9, and -13, fibroblast-like synoviocytes (FLSCs) have been implicated in the process of marginal cartilage erosion and joint destruction in rheumatoid arthritis (RA) (1, 2, 3, 4, 5, 6, 7, 8). Accordingly, the intracellular pathways through which FLSC activities are regulated have become a subject of increasing interest. Signaling and/or regulatory molecules implicated in the proliferative and/or degradative activities of FLSCs include the mitogen-activated protein kinases (MAPKs) c-Jun N-terminal kinase (JNK) and p38 (9, 10), the tumor suppressor p53 (11, 12), the proinflammatory transcription factor NF-B (13), and possibly telomerase (14). However, the precise role of each of these in inflammatory joint destruction remains to be fully elucidated.

In contrast with JNK and p38, which are activated in response to inflammatory and stress signals, the MAPK extracellular signal-regulated kinase (ERK) has been most thoroughly studied in the context of growth factor stimulation and is primarily appreciated as playing roles in cell proliferation, antiapoptosis, and differentiation (15, 16, 17, 18, 19, 20, 21). However, ERK may also be activated in response to proinflammatory stimuli (22, 23). For example, Vilcek and colleagues (24, 25, 26) have demonstrated that in FS-4 fibroblasts, ERK undergoes activation in response to the cytokines IL-1 and TNF-, both of which are critical to the pathogenesis of RA. The ability of fibroblast ERK to respond to inflammatory cytokines, as well as to signal for cell proliferation, suggests that the ERK signaling pathway might be an important regulator of FLSC functions.

Nonsteroidal anti-inflammatory drugs (NSAIDs) constitute a diverse family of agents that share an ability to inhibit cyclooxygenase (COX) activity and PG production (27, 28, 29). Nonetheless, COX inhibition may not entirely account for the actions of some NSAIDs. For instance, high concentrations of aspirin (ASA) and other salicylates have recently been shown to inhibit inducible NO synthase expression and activity (30), to inhibit NF-B activation (31), to stimulate the activation of p38 (32), and to stimulate apoptosis, probably via p38 activation (33). These effects were COX-independent and not shared by nonsalicylate NSAIDs such as indomethacin. Our laboratory (34) and Vilcek and colleagues (25) have observed the capacity of high doses of ASA and sodium salicylate (NaS) to inhibit ERK in neutrophils (34) and FS-4 fibroblasts (25), respectively. In our studies, the effects of salicylates on ERK were COX independent and directly tied to their ability to inhibit neutrophil inflammatory responses such as stimulated adhesion.

Based on these prior observations, we were interested to know, first, whether the ERK pathway plays a prominent role in FLSC signaling and, second, whether salicylates or other NSAIDs might be effective in modifying such signaling. Our data suggest that ERK activation in FLSCs selectively mediates the extracellular expression of some, but not all, MMPs. Salicylates, via effects on ERK, may play an important, potentially disease-modifying role in the down-regulation of MMPs. In contrast, we were surprised to observe that COX inhibition enhances the expression of MMP-1 by FLSCs, via effects on PGE-mediated inhibition of ERK-dependent MMP-1 production.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials

Unless otherwise noted, all reagents were from Sigma-Aldrich (St. Louis, MO). Cultures of transformed rabbit FLSCs (HIG-82) (35) were from American Type Culture Collection (Manassas, VA; catalogue no. CRL-1832). Anti-phosphoERK (catalog no. sc-7383), anti-phosphoJNK (catalog no. sc-6254), anti-phosphotyrosine (catalog no. sc-508), anti-ERK-1 (catalog no. sc-93), anti- ERK2 (catalog no. sc-154), and HRP-conjugated donkey anti-mouse (catalog no. sc-2004) Abs and antisera were from Santa Cruz Biotechnology (Santa Cruz, CA). In some experiments, anti-phosphoERK antiserum was from Promega (Madison, WI; catalog no. V8031); SB203580 was also from Promega. UO126 was from Upstate Biotechnology (Lake Placid, NY). PD98059 was from Biomol (Plymouth Meeting, PA). Anti-MMP-1 (catalog no. AB806), anti-MMP-3 (catalogue no. AB812), and anti-MMP-9 (catalog no. AB805) antisera were from Chemicon International (Temecula, CA). Anti-MMP-13 antiserum (catalog no. AF511) and PGE₁ immunoassay kit were from R&D Systems (Minneapolis, MN). Precast 10% Tris-glycine/polyacrylamide gels were from Novex/Invitrogen (San Diego, CA). Nitrocellulose paper was from Schleicher & Schuell (Keene, NH). [¹²⁵I]Protein A and ECL detection kit were from Amersham (Arlington Heights, IL). Centricon centrifugal filter devices were from Millipore (Bedford, MA). Ham’s F-12 medium and FBS were from BioWhittaker (Walkersville, MD). Penicillin G sodium (10,000 U/ml)/streptomycin sulfate (10,000 µg/ml) in 0.85% NaCl was from Life Technologies (Rockville, MD). NS398 was from CalBiochem (La Jolla, CA). The selective COX-2 inhibitor SC299 was the kind gift of K. Seibert and J.J. Talley (Searle Research and Development, Skokie, IL). 6-Methoxy-2-naphthylacetic acid (6MNA) was the kind gift of Darren Rimmer and Peter G. Treagust (GlaxoSmithKline, Essex, U.K.).

FLSC culture and preparation for experiments

Except where specified, all experiments were performed on rabbit FLSCs (35). FLSCs were grown in Ham’s F-12 medium containing 10% FBS and 1% penicillin/streptomycin, as recommended by the supplier. For experimental purposes, FLSCs were seeded into six-well plates, grown to near confluence, and then serum starved (Ham’s F-12 without FBS or penicillin/streptomycin) for 24–48 h. Protein assays of cell lysates, performed after serum starvation, confirmed that cell populations before experimentation differed by no more than 10% between wells.

Human rheumatoid FLSCs were prepared by a modification of the method of Alvaro-Gracia et al. (36). Synovium obtained from RA patients at the time of joint replacement was minced with a sterile scalpel in 90-mm plates and was treated with collagenase (1 mg/ml) in DMEM for three cycles each of 30 min at room temperature. After each collagenase exposure, the plates were gently agitated and the supernatant, containing free FLSCs, was aspirated and set aside. The total supernatant from the three incubations was pooled, washed three times in DMEM, and cultured in DMEM containing 10% FCS as well as 1% penicillin/streptomycin and L-glutamine. Cells were grown at 37°C and used in experiments between passages three and eight.

Measurement of ERK activation

After serum starvation of FLSCs, supernatants were removed and replaced with fresh Ham’s F-12 medium for 30–60 min at 37°C/5% CO₂ before experimental treatments as described in Results and the figure legends. Except where otherwise specified, cells were exposed to inhibitors for 30 min and to stimuli for 30 min. Subsequent to experimental treatment, cells were incubated with ice-cold lysis buffer (20 mM Tris (pH 7.4), 1 mM EGTA, 2 mM sodium vanadate, 25 mM sodium fluoride, 0.5% (v/v) Triton X-100, 2 mM PMSF, 10⁵ KU/ml aprotinin, and 10 µg/ml each of chymostatin, antipain and pepstatin) for 20 min at 4°C. The adherent remnants were liberated with a rubber policeman, and the lysates were collected and supplemented with Laemmli sample buffer (37) containing 5% 2-ME. Samples were heated (100°C for 3–5 min) and analyzed by SDS-PAGE on 10% Tris-glycine gels, followed by electrophoretic transfer to nitrocellulose. Nitrocellulose papers were imaged with Ponceau S solution to confirm even loading of the gel lanes, washed three times with TBS (pH 7.4) containing 0.05% Tween 20, blocked with 3% BSA in TBST for 1 h, washed three times again, and immunoblotted with anti-phosphoERK antiserum in TBST at a dilution of 1/200 for 1 h. The blots were again washed three times with TBST, followed by 1-h incubation with [¹²⁵I]protein A and further washing and drying. The blots were imaged and quantitated using a PhosphorImager (Storm imaging system; Molecular Dynamics, Sunnyvale, CA). A similar protocol was used for determining JNK activation using an anti-phosphoJNK Ab; the image was analyzed using a secondary HRP-conjugated Ab, chemiluminescence according to the manufacturer’s instructions, and autoradiography. Duplicate samples from each experiment were treated similarly but analyzed on immunoblot using Abs that recognize both phosphorylated and unphosphorylated ERK 1 and 2 (each Ab at 1/200) or JNK to confirm that changes in levels of the phosphoenzymes were not due to changes in total enzyme expression.

MMP expression in the extracellular fluid

FLSC cultures grown to near confluence in six-well plates were serum starved (0% FBS, without penicillin/streptomycin) for 24–48 h. The supernatants were removed and replaced with fresh Ham’s F-12 and, after allowing 30–60 min for equilibration, the cultures were treated and stimulated as described in Results and the figure legends. The supernatants were recovered and concentrated by centrifugation in Centricon centrifugal filter devices (m.w. cutoff 30,000) for 35 min at 5000 rpm at 4°C. Aliquots of the concentrated supernatants were supplemented with Laemmli buffer and analyzed for the presence of MMP-1, -3, -9, and -13 by SDS-PAGE (10% Tris-glycine gels), transfer to nitrocellulose, immunoblotting with the appropriate anti-MMP Ab (1/200), and visualization via [¹²⁵I]protein A and phospor imaging.

Measurement of PGE₁

PGE₁ in the supernatant was measured by ELISA, according to the manufacturer’s directions.

Quantification of ATP by HPLC

FLSCs grown to near confluence were incubated overnight ±10 mM ASA or NaS, lysed, and centrifuged as described for Western blotting (see Measurement of ERK activation). The aqueous phase of sample supernatants was transferred into fresh sample tubes for HPLC analysis using a Spherisorb S5 SAX column (Waters, Milford, MA) with a KCl gradient of 0.007–0.25 M formed over 80 min. ATP was identified by its characteristic retention time and UV absorbance spectrum. Quantitation was achieved by comparison to known standards using Millennium32 software (v3.05.01; Waters). 2-Chloroadenosine, which has a different retention time and absorbance, was used as an internal control and was added to the samples at the time of sample preparation.

Statistical evaluation

Immunoblots imaged by phosphor imaging and/or autoradiography were quantitated using ImageQuant (Molecular Dynamics). Because the units of such quantitation are arbitrary and vary in magnitude between experiments, either the unstimulated or stimulated condition, as appropriate, was normalized to 100% for purposes of evaluation. The remaining conditions were then expressed relative to the normalized control values. Unless otherwise stated, all experiments were done three times in duplicate. Significant differences between the control and variable conditions in each experiment were determined by unpaired or paired Student’s t test, as appropriate, using Microsoft Excel X (Redmond, WA) for Macintosh (Apple Computer, Cupertino, CA).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Activation of ERK by IL-1 and TNF- in FLSCs

Stimulation of rabbit FLSCs with IL-1 (20 ng/ml) and/or TNF- (20 ng/ml) for 30 min resulted in increased ERK activation relative to unstimulated controls. Consistent with a prior report (38), IL-1 was a more effective stimulus, and TNF- stimulation of ERK did not independently reach statistical significance (IL-1 stimulation of ERK 2, 150 ± 16% control, p = 0.027; TNF- stimulation of ERK 2, 128 ± 22% control, p = 0.146) (Fig. 1, A and C). Stimulation of FLSCs simultaneously with both agents resulted in increased ERK phosphorylation relative to either alone (200 ± 33% control; p = 0.028). Both ERK 1 (p44) and ERK 2 (p42) underwent activation. Similar results were observed with human FLSCs obtained from the knees of patients undergoing joint replacement for RA (Fig. 1B). To confirm that increases in the phosphorylated form of ERK were due to activation and not to changes in total expression of ERK protein, lysates from these experiments were analyzed for total ERK expression. Stimulation with IL-1, TNF-, or both did not affect total amounts of ERK (data not shown). ERK 2 was consistently more abundant than ERK 1; in some experiments, levels of activated ERK 1 were so limited as to preclude quantitative analysis. Consistent with a previous report on IL-1-stimulated human RA cells (9), IL-1/TNF--stimulated activation of ERK in rabbit FLSCs was rapid and transient, peaking at 15–30 min (Fig. 1D; at t = 15 min, ERK 2 activity = 146% control, p = 0.029; at t = 30 min, ERK activity = 135% control, p = 0.018). Because IL-1 and TNF- together induced more ERK stimulation than either agent alone and because in RA joints FLSCs are exposed to both of these cytokines simultaneously, subsequent experiments were conducted using IL-1 and TNF- as costimuli.

View larger version (21K): [in this window] [in a new window]   FIGURE 1. IL-1 and TNF- stimulate ERK activation in FLSCs. A, Rabbit FLSCs were stimulated with IL-1, TNF-, or both for 30 min at 37°C, lysed, and analyzed for ERK activation by SDS-PAGE and immunoblotting with anti-phosphoERK Ab. B, Human RA FLSCs were stimulated and analyzed for ERK activation as in A. C, Mean ± SEM values of IL-1- and/or TNF--stimulated levels of ERK 2 phosphorylation in rabbit FLSCs for three experiments including that in A. D, Time course for rabbit FLSC ERK activation in response to IL-1+TNF-. Data shown are representative of the mean ± SEM of two (B), three (D), or four (A and C) experiments for each condition (**, p 0.05; *, p 0.1; relative to unstimulated control).

PD98059 (39) and UO126 (40) are specific inhibitors of the proximal ERK activator MEK. As shown in Fig. 2A, incubation of FLSCs with PD98059 (100 µM) before stimulation with IL-1 and TNF- resulted in 56 ± 7% (p = 0.002) inhibition of maximally stimulated ERK activation levels. Consistent with previous reports in other cell types (40), UO126 (10 µM) was a more effective inhibitor of ERK, producing 80 ± 14% (p = 0.005) inhibition. In separate experiments, PD98059 and UO126 also inhibited baseline levels of ERK activity in the absence of stimulation, indicating that, even under conditions of serum starvation, these rabbit FLSCs are not completely quiescent vis-a-vis ERK activity (data not shown). At concentrations 10 µM, SB203580 is a specific inhibitor of another MAPK, p38 (41). In contrast with PD98059 and UO126, SB203580 (10 µM) failed to inhibit ERK activation stimulated by IL-1/TNF- (17 ± 8% enhancement of IL-1/TNF- stimulation, p = 0.063).

View larger version (24K): [in this window] [in a new window]   FIGURE 2. ERK regulates extracellular expression of MMP-1 but not MMP-13 in FLSCs. A, Rabbit FLSCs were incubated for 30 min ± PD98059 (100 µM), UO126 (10 µM), or SB203580 (10 µM), stimulated (20 ng/ml IL-1/TNF-) for 30 min, and analyzed for ERK activation. B, FLSCs treated as in A were stimulated for 18 h, and the supernatants were analyzed for MMP-1 and MMP-13. C, FLSCs were incubated ± UO126 (10 µM) or SB203580 (10 µM), followed by EGF (200 ng/ml) stimulation for 30 min for analysis of ERK activation (top) or 18 h for measurement of extracellular MMP-1 (middle) or MMP-13 (bottom). Data are representative of the mean ± SEM of three (C) or four (A and B) experiments for each condition.

To further investigate the role of ERK in regulating MMP-1, we tested the effects of epidermal growth factor (EGF), a canonical activator of ERK, on FLSCs. Stimulation of FLSCs with EGF resulted in ERK activation and preincubation with UO126, but not SB203580, inhibited ERK activation (Fig. 2C, top). Stimulation of FLSCs with EGF also resulted in increased MMP-1 release, which was inhibited by UO126, but not SB203580 (Fig. 2C, middle). These data provide additional evidence for a role for ERK, but not p38, in the regulation of MMP-1 release from cells. In contrast, EGF stimulation of MMP-13 release was not inhibited by either UO126 or SB203580 (Fig. 2C, bottom).

ASA inhibits ERK activation in a COX-independent manner

We have previously demonstrated that millimolar (clinically anti-inflammatory) but not micromolar (analgesic, COX-inhibiting) concentrations of ASA inhibit ERK activation in human neutrophils (34). As shown in Fig. 3A, 10 mM ASA also inhibited IL-1/TNF- stimulation of ERK 1 (24 ± 6% inhibition, p = 0.020) and ERK 2 (35 ± 10% inhibition, p = 0.005) in FLSCs. To determine whether the ability of ASA to inhibit ERK was shared by other NSAIDs (i.e., whether it was COX-dependent), we tested the effects of nonselective COX inhibitors on ERK activation by IL-1 plus TNF-. Exposure of FLSCs to indomethacin for 30 min at concentrations sufficient to inhibit both COX-1 and -2 (10 µM) had little or no effect on ERK activation. Similarly, 30-min exposure to levels of ibuprofen (100 µM) or 6MNA (50 µM) sufficient to inhibit both COX-1 and -2 (43) had no significant effect on ERK. Thus, stimulation of ERK via IL-1/TNF- depends upon neither the rapid activation of COX nor the stimulated production of PGs.

View larger version (24K): [in this window] [in a new window]   FIGURE 3. Effects of ASA and nonselective COX inhibitors on ERK and MMP-1 release from FLSCs. A, Rabbit FLSCs were incubated ± ASA, indomethacin, ibuprofen, or 6MNA, followed by IL-1/TNF- stimulation (20 ng/ml each). Cells were lysed and analyzed for ERK activation. B, FLSCs treated as in A were stimulated ± IL-1/TNF- for 18 h and were analyzed for MMP-1 in the supernatant. Data shown are the mean ± SEM of four or more experiments for each condition.

View larger version (41K): [in this window] [in a new window]   FIGURE 4. Effects of salicylates on FLSC survival, metabolic activity, phosphorylation capacity, and JNK activation. A, Rabbit FLSCs were incubated overnight ± 10 mM ASA or NaS and were analyzed for cell death measured as lactate dehydrogenase release (filled bars) or viability measured as trypan blue exclusion compared with untreated controls (hatched bars). B, FLSCs were incubated overnight ± 10 mM ASA or NaS, lysed, and analyzed for lysate ATP levels. C, FLSCs were incubated overnight ± 10 mM ASA or NaS and were stimulated for 30 min with IL-1/TNF-, and lysates of the cells were analyzed by anti-phosphotyrosine immunoblotting. D, FLSCs were incubated for 1 h ± 10 mM ASA or NaS, followed by stimulation for 15 min with IL-1/TNF- and analysis for JNK activation by anti-phosphoJNK immunoblotting. Data shown are representative of the mean ± SEM of three experiments for each condition.

Because millimolar concentrations of ASA inhibited ERK, we reasoned that they should also inhibit extracellular MMP-1 expression from FLSCs. As shown in Fig. 3B, pre-exposure of FLSCs to 10 mM ASA inhibited IL-1/TNF- stimulation of MMP-1 release (29 ± 9% inhibition, p = 0.029). To confirm that this effect of ASA was not due to inhibition of COX, we tested the effects of indomethacin, ibuprofen, and 6MNA. Strikingly, these agents did not merely fail to inhibit MMP-1 release, but they enhanced the release of MMP-1 from these stimulated cells (indomethacin, 140 ± 18% (p = 0.088); ibuprofen, 147 ± 14% (p = 0.045); 6MNA, 191 ± 23% (p = 0.014); above IL-1/TNF--stimulated levels). Thus, millimolar salicylates inhibit, but COX inhibitors enhance, MMP-1 release. To examine this observation in more detail, we performed dose-response experiments comparing ASA (potent COX inhibitor, IC₅₀ 1.7 µM for COX-1, 7.5 µM for COX-2 (43)) with NaS (weak COX inhibitor, IC₅₀ 5 mM for COX-1, 500 mM for COX-2 (43)). As shown in Fig. 5A, micromolar concentrations of ASA had no effect on ERK, but inhibited COX activity measured by extracellular PGE₁ expression and resulted in increased MMP-1 release from IL-1/TNF--stimulated cells (32 ± 15% increase in MMP-1 above IL-1/TNF- at 10 µM ASA concentrations (p = 0.048)). In contrast, micromolar concentrations of NaS did not affect either COX or MMP-1 (Fig. 5B). At millimolar concentrations, NaS reproduced ASA’s ability to inhibit both ERK and MMP-1 release. The IC₅₀ for both ASA and NaS, for both ERK 1/2 and MMP-1 inhibition, were 1 mM. We also tested the effects of micromolar and millimolar ASA on ERK activation and MMP-1 expression in response to EGF. As shown in Fig. 5C (top), stimulation of ERK by EGF was unaffected by 10 µM ASA, but was inhibited by 10 mM ASA. Consistent with the effects seen in IL-1/TNF--stimulated cells, 10 µM ASA enhanced but 10 mM ASA inhibited EGF-stimulated MMP-1 expression (Fig. 5C, bottom). Thus, both acetylated and nonacetylated salicylates, at concentrations sufficient to inhibit ERK, inhibit MMP-1 production. However, ASA differs from NaS in that at lower concentrations that do not inhibit ERK, ASA inhibits COX and enhances MMP-1 production.

View larger version (20K): [in this window] [in a new window]   FIGURE 5. Biphasic dose response of ASA for IL-1/TNF--stimulation of ERK activation and extracellular MMP-1 expression. Rabbit FLSCs were preincubated with ASA (A) or NaS (B) for 30 min, followed by stimulation ± IL-1/TNF- and analysis for ERK activation (30-min stimulation) or extracellular MMP-1 or PGE1 expression (18- and 6-h stimulation, respectively). C, FLSCs were incubated ± UO126, SB203580, or 10 µM or 10 mM ASA, followed by EGF stimulation and analysis for ERK activation (top) or extracellular MMP-1 expression (bottom). Data are representative of the mean ± SEM of three or four experiments for each condition (**, p 0.05; *, p 0.08; relative to IL-1/TNF--stimulated control).

View larger version (18K): [in this window] [in a new window]   FIGURE 6. Selective COX-2 inhibitors enhance IL-1/TNF--stimulated MMP-1 expression. Rabbit FLSCs were incubated ± NS398, celecoxib, or SC299 for 30 min, followed by stimulation with IL-1/TNF- and analysis for ERK 1/2 activation (A) or extracellular MMP-1 expression (B). Data shown are the mean ± SEM of three experiments for each condition.

To confirm that COX-2 down-regulates MMP-1 through production of PGs, we tested the effects of E- and F-series PGs on extracellular MMP-1 expression. As shown in Fig. 7A, incubation of FLSCs with either PGE₁ (1 µM) or PGE₂ (1 µM) before stimulation with IL-1/TNF- resulted in significant inhibition of MMP-1 release. Consistent with prior reports in FLSCs stimulated with phorbol myristate acetate (46, 47), PGE₁ appeared to be a more efficient inhibitor of MMP-1 expression (PGE₁, 38 ± 4% inhibition (p = 0.0002); PGE₂, 29 ± 6% inhibition (p = 0.035)). Higher concentrations of PGE₁ (10 µM) were more efficacious at inhibiting stimulation of extracellular MMP-1 expression (60% inhibition; data not shown). In contrast, neither 1 µM PGF₂ nor 10 µM PGF₂ (data not shown) inhibited stimulated MMP-1 expression (1 µM PGF₂, 3 ± 12% inhibition, p = 0.326). Thus, the effect of PGEs on MMP-1 release appeared to be class specific and not a general lipid or PG effect. To further relate the effects of PGs to the effects of COX inhibition, we tested the capacity of PGE₁ to reverse the effects of the selective COX-2 inhibitor NS398 on extracellular MMP-1 expression. As shown in Fig. 7B, incubation of FLSCs in the simultaneous presence of PGE₁ and NS398 abrogated the ability of NS398 to enhance MMP-1 production, suggesting that enhancement of extracellular MMP-1 expression by COX inhibitors occurs through the inhibition of PGE production.

View larger version (41K): [in this window] [in a new window]   FIGURE 7. E PGs inhibit IL-1/TNF- stimulation of ERK and MMP-1 expression and reverse the effect of a COX inhibitor on MMP-1. A, Rabbit FLSCs were incubated ± PGE1, PGE2, or PGF2 (each 1 µM) for 30 min, stimulated overnight with IL-1/TNF-, and analyzed for extracellular MMP-1 expression. B, FLSCs were incubated ± PGE1 (1 µM), NS398 (0.5 µM), or both, stimulated with IL-1/TNF-, and analyzed for extracellular MMP-1 expression. C, FLSCs treated as in A and stimulated for 30 min were analyzed for ERK activation. D, Human RA FLSCs were incubated ± 50 µM PD98059 or 1 µM PGE1, stimulated with IL-1/TNF-, and analyzed for ERK activation (top) and total ERK (bottom). Data shown are representative or the mean ± SEM of three (B–D) or four (A) experiments for each condition.

2

2

NSAID enhancement of extracellular MMP-1 expression is mediated through an ERK-dependent signaling pathway

The ability of PGEs to down-regulate extracellular MMP-1 expression, together with the constitutive presence COX-2 in FLSCs, suggested that even in cells that are not exogenously stimulated, PGE production might contribute to autacoid control of baseline MMP-1 expression levels. To test this hypothesis, FLSCs were incubated in the presence of various selective and nonselective COX inhibitors overnight in the absence of cytokine stimulation, and the supernatants were assayed for the presence of MMP-1. As shown in Fig. 8A, incubation of FLSCs with 10 µM NaS (weak COX inhibitor) had no effect on baseline MMP-1 levels in the extracellular fluid (111 ± 7% control, p = 0.087). However, 100 µM ibuprofen and 0.5 µM SC299 each caused an increase in extracellular MMP-1 (ibuprofen, 177 ± 21% control (p = 0.003); SC299, 230 ± 32% control (p = 0.005)) in the absence of additional stimuli. NS398 was also tested and increased extracellular MMP-1 expression (132 ± 10% control, p = 0.011; data not shown). Thus, FLSCs in culture appear to maintain a program of baseline MMP-1 production that is tonically down-regulated by PGEs.

View larger version (22K): [in this window] [in a new window]   FIGURE 8. COX regulation of MMP-1 expression in FLSCs is ERK-dependent. A, Rabbit FLSCs were incubated ± NaS, ibuprofen, or SC299 for 18 h at 37°C, and the supernatants were analyzed for MMP-1. B, FLSCs were incubated ± ibuprofen, PGE1, PGF2, UO126, or SB203580 for 18 h at 37°C and were analyzed for supernatant MMP-1 levels (top). The experiment at the top was duplicated, substituting the selective COX-2 inhibitor SC299 for ibuprofen (bottom). C, FLSCs were incubated for 18 h at 37°C, with staggered addition of 100 µM ibuprofen resulting in exposure for the indicated times. The supernatants and cell lysates were simultaneously analyzed for PGE1 expression and ERK activation, respectively. Data shown are representative of the mean ± SEM of three (B and C) or five (A) experiments for each condition (**, p 0.05, relative to unstimulated control).

2

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
FLSCs are the most numerous cells in rheumatoid synovium and, via their ability to proliferate and produce cytokines, PGs, and metalloproteinases, are implicated in cartilage destruction in RA. Pharmacologic agents that regulate FLSC signaling and metalloproteinase expression thus provide insight into synovial biology and possible future therapies for RA. Our studies indicate that both E-series PGs and salicylates inhibit FLSC production of MMP-1 through inhibition of ERK. In contrast, COX inhibitors enhance MMP-1 production via depletion of E PGs and consequent enhancement of ERK activation.

We first examined the role of ERK in IL-1/TNF--dependent FLSC signaling. ERK was activated in response to IL-1/TNF-, and the selective MEK inhibitors PD98059 and UO126 inhibited ERK activation. Moreover, MMP-1 but not MMP-13 production was inhibited as a result of ERK pathway inhibition. ERK also regulated the expression of MMP-3 and -9, a fact of potential clinical importance, because MMP-3 cleaves and activates MMP-1 both in vitro and in vivo (48). Thus, ERK activation in FLSCs selectively regulates the cytokine-stimulated, extracellular expression of some but not all MMPs. To our knowledge, ours is the first demonstration that ERK regulates FLSC expression of MMP-1 protein in response to cytokines found in the rheumatoid joint. However, our data are consistent with reports by Han et al. (9, 10) that PD98059 inhibits TNF--stimulated increases in MMP-1 message in FLSCs and by Sun et al. (49) that induction of the FLSC MMP-1 promoter by calcium phosphate crystals is ERK-dependent. In chondrosarcoma cells, Mengshol et al. (50) have shown that PD98059 inhibits TNF--stimulated expression of MMP-1 but not MMP-13. One way in which our data vary from these other authors is in our concurrent use of IL-1 and TNF- as costimuli. However, we also observed similar effects in experiments in which IL-1 or TNF- was used separately (data not shown). Moreover, EGF stimulation of MMP-1 but not MMP-13 expression was also ERK dependent, suggesting that ERK regulates MMP-1 release in response to a variety of different stimuli.

We have previously demonstrated that millimolar but not micromolar concentrations of salicylates inhibit ERK in human neutrophils (34), and Schwenger et al. (25) have documented a similar effect in FS-4 fibroblasts stimulated with TNF-. We now confirm that millimolar concentrations of ASA and NaS inhibit ERK activation in FLSCs. It is unlikely that the effects of salicylates on FLSC ERK were due to COX inhibition because micromolar concentrations of ASA did not inhibit ERK, despite their ability to inhibit COX both historically (43) and in our experiments. Moreover, neither nonsalicylate NSAIDs (ibuprofen, indomethacin, and 6MNA) nor selective COX-2 inhibitors (NS398, celecoxib, and SC299) inhibited ERK activation. Indeed, if ASA were to inhibit ERK via inhibition of COX, then PGs would be expected to stimulate ERK activation. In contrast, we observed that PGEs inhibited FLSC ERK activation. The mechanism of this inhibition was not determined, but probably relates to the ability of E-prostanoid₂ receptors to activate adenyl cyclase, leading to cAMP accumulation, protein kinase A (PKA) activation, and ERK pathway inhibition at the level of Raf-1 interaction with 14-3-3 proteins (51, 52, 53). Consistent with such a model, E-series PGs inhibit ERK in neutrophils in a cAMP- and PKA-dependent fashion (23, 54, 55). In FLSCs, we have observed that the cell-permeable cAMP analog dibutyryl cAMP inhibited IL-1/TNF--stimulated ERK activation (M.H.P. and P.B.R., unpublished observation).

Consistent with their effects on ERK, millimolar concentrations of salicylates also inhibited MMP-1 expression. The inhibitory effects of salicylates on MMP-1 were unrelated to COX inhibition because 1) the doses of ASA required exceeded those required to inhibit COX and 2) the ability of salicylates to inhibit MMP-1 was not duplicated by nonsalicylate NSAIDs. On the contrary, COX-inhibiting concentrations of ASA as well as ibuprofen, indomethacin, and 6MNA enhanced rather than inhibited IL-1/TNF--stimulated MMP-1 release. This phenomenon was COX-2 dependent because selective COX-2 inhibitors also enhanced MMP-1 expression. These observations are consistent with reports by Dayer et al. (56) that indomethacin stimulated collagenase production in rheumatoid FLSCs and by He et al. (57) that NS-398 induced MMP-1 synthesis in synovial explants from patients with osteoarthritis. Therefore, we hypothesized that production of one or more PGs by COX enzymes suppresses cytokine-stimulated MMP-1 expression by FLSCs. In fact, we observed that exogenous PGEs, but not PGF₂, inhibited IL-1/TNF--stimulated MMP-1 expression, and PGE₁ reversed the effects of NS398 on MMP-1. Consistent with these observations, both DiBattista et al. (58, 59) and Bockman and colleagues (46, 47) have reported that PGEs suppressed the expression of MMP-1 in a cAMP- and PKA-dependent fashion. Taken together, these data suggest that the mechanism through which COX inhibitors enhance MMP-1 levels depends on their ability to block the production of E-series PGs. Indeed, the ability of COX inhibitors to induce MMP-1 expression in the absence of additional stimuli suggests that baseline PG production exerts a tonic inhibitory effect on the cellular production of MMPs.

As noted above, brief exposure of FLSCs to COX inhibitors had no effect on ERK activation, indicating that rapid, stimulated production of PGs does not mediate ERK activity. Nonetheless, the ability of exogenous E PGs to inhibit both ERK and MMP-1 suggested that COX-2 might regulate MMP-1 by synthesizing endogenous PGEs that inhibit ERK. Consistent with this hypothesis, the enhancing effects of both ibuprofen and SC299 on MMP-1 in the absence of cytokines could be abrogated by either PGE supplementation or pharmacologic ERK inhibition. Moreover, in contrast with the lack of effect of brief exposures to COX inhibitors (which did not affect pre-existing PGE concentrations), extended exposures to ibuprofen of sufficient duration to cause observable decrements in extracellular PGE levels transiently stimulated ERK activity. Thus, whereas millimolar salicylates appear to inhibit MMP-1 expression through effects on ERK, COX inhibitors appear to enhance MMP-1 expression through the very same pathway. In Fig. 9, we have provided a best-fit model for this counter-regulation. Because cytokines stimulate ERK and also up-regulate COX-2 expression, which may then down-regulate ERK via PGE production, this model suggests a possible system of feedback inhibition.

View larger version (12K): [in this window] [in a new window]   FIGURE 9. Best-fit model mapping the regulation of MMP-1 expression by ERK and the regulation of ERK via salicylates and PGs. Our current studies suggest that production of MMP-1, -3, and -9 in response to EGF, IL-1, and/or TNF- depends upon ERK activation and that PGE production by COX-2 down-regulates ERK-mediated production of MMP-1. Agents that inhibit COX (including micromolar ASA) therefore enhance ERK activation and secondarily enhance MMP-1, -3, and -9 production, whereas agents that inhibit the ERK pathway (including millimolar ASA) secondarily inhibit MMP-1, -3, and -9 production. MMP-13 is also activated by IL-1/TNF-, but in an ERK-independent manner. Because IL-1/TNF- not only activate ERK but also stimulate PGE production via COX-2 up-regulation, the possibility of a regulatory loop is suggested by these data. (Solid arrows indicate stimulation, dashed arrows indicate inhibition.) Based on historical reports from the literature (9 10 ), a salicylate-independent role for JNK in this pathway is also included here.

	Acknowledgments

 
We thank Madeline Rios for her excellent editorial and administrative support, Robert M. Clancy and Clifton Bingham III for helpful discussions, and Nada Marjanovic and Avani Desai for technical assistance.

	Footnotes

 
¹ This work was supported by Young Scholar and Research Grants (to M.H.P.) and Fellowship Grants (to P.B.R.) from the Arthritis Foundation (New York Chapter), by National Institutes of Health Training Grant T32 AR07176-26, and by a generous gift from the Sophie and Joseph Abeles Foundation (to S.B.A.).

² Address correspondence and reprint requests to Dr. Michael H. Pillinger, Division of Rheumatology, Department of Medicine 630-111J, New York Harbor Healthcare System, 423 East 23rd Street, New York, NY 10010. E-mail address: michael.pillinger{at}med.nyu.edu

³ Abbreviations used in this paper: MMP, matrix metalloproteinase; FLSC, fibroblast-like synoviocyte; RA, rheumatoid arthritis; MAPK, mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; ERK, extracellular signal-regulated kinase; NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; ASA, aspirin; NaS, sodium salicylate; 6MNA, 6-methoxy-2-napthylacetic acid; MEK, MAPK/ERK kinase; EGF, epidermal growth factor; PKA, protein kinase A.

Received for publication January 3, 2003. Accepted for publication September 22, 2003.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Yamanishi, Y., G. S. Firestein. 2001. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum. Dis. Clin. N. Am. 27:355.[Medline]
2. Murphy, G., V. Knauper, S. Atkinson, G. Butler, W. English, M. Hutton, J. Stracke, I. Clark. 2002. Matrix metalloproteinases in arthritic disease. Arthritis Res. 4:S39.
3. Edwards, J. C. W.. 1998. The synovium. R. N. Maini, and N. J. Zvaifler, and J. H. Klippel, and P. A. Dieppe, eds. Rheumatology 2nd Ed.6.1. Mosby, London.
4. Firestein, G. S.. 1998. Rheumatoid synovitis and pannus. R. N. Maini, and N. J. Zvaifler, and J. H. Klippel, and P. A. Dieppe, eds. Rheumatology 2nd Ed.13.1. Mosby, London.
5. Vincenti, M. P., C. I. Coon, J. A. Mengshol, S. Yocum, P. Mitchell, C. E. Brinckerhoff. 1998. Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1). Biochem. J. 331:341.
6. Green, M. J., A. K. S. Gough, J. Devlin, J. Smith, P. Astin, D. Taylor, P. Emery. 2003. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 42:83.[Abstract/Free Full Text]
7. Cunnane, G., O. Fitzgerald, K. M Hummel, P. P. Youssef, R. E. Gay, S. Gay, B. Bresnihan. 2001. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum. 44:1744.[Medline]
8. Martel-Pelletier, J., D. J. Welsch, J.-P. Pelletier. 2001. Metalloproteases and inhibitors in arthritic diseases. Best Pract. Res. Clin. Rheumatol. 15:805.[Medline]
9. Han, Z., D. L. Boyle, K. R. Aupperle, B. Bennett, A. M. Manning, G. S. Firestein. 1999. Jun N-terminal kinase in rheumatoid arthritis. J. Pharmacol. Exp. Ther. 291:124.[Abstract/Free Full Text]
10. Han, Z., D. L. Boyle, L. Chang, B. Bennett, M. Karin, L. Yang, A. M. Manning, G. S. Firestein. 2001. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammation arthritis. J. Clin. Invest. 108:73.[Medline]
11. Firestein, G. S., F. Echeverri, M. Yeo, N. J. Zvaifler, D. R. Green. 1997. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arhthritis synovium. Proc. Natl. Acad. Sci. USA 94:10895.[Abstract/Free Full Text]
12. Yamanishi, Y., D. L. Boyle, M. J. Pinkoski, A. Mahboubi, T. Lin, Z. Han, N. J. Zvaifler, D. R. Green, G. S. Firestein. 2002. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am. J. Pathol. 160:123.[Abstract/Free Full Text]
13. Vincenti, M. P., C. I. Coon, C. E. Brinckerhoff. 1998. Nuclear factor B/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1-stimulated synovial fibroblasts. Arthritis Rheum. 41:1987.[Medline]
14. Yudoh, K., H. Matsuno, T. Nezuka, T. Kimura. 1999. Different mechanisms of synovial hyperplasia in rheumatoid arthritis and pigmented villonodular synovitis: the role of telomerase activity in synovial proliferation. Arthritis Rheum. 42:669.[Medline]
15. Zhang, S., J. Han, M. A Sells, J. Chernoff, U. G. Knaus, R. J. Ulevitch, G. M. Bokoch. 1995. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J. Biol. Chem. 270:23934.[Abstract/Free Full Text]
16. Wartmann, M., R. J. Davis. 1994. The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J. Biol. Chem. 269:6695.[Abstract/Free Full Text]
17. Leevers, S. J., H. F. Paterson, C. J. Marshall. 1994. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369:411.[Medline]
18. Stokoe, D., S. G. Macdonald, K. Cadwallader, M. Symons, J. F. Hancock. 1994. Activation of raf as a result of recruitment to the plasma membrane. Science 264:1463.[Abstract/Free Full Text]
19. Kyriakis, J. M., H. App, X.-F. Zhang, P. Banerjee, D. L. Brautigan, U. R. Rapp, J. Avruch. 1992. Raf-1 activates MAP kinase-kinase. Nature 358:417.[Medline]
20. Crews, C. M., R. L. Erikson. 1992. Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product. Proc. Natl. Acad. Sci. USA 89:8205.[Abstract/Free Full Text]
21. Cobb, M. H., J. R. Hepler, M. Cheng, D. Robbins. 1994. The mitogen-activated protein kinases, ERK1 and ERK2. Semin. Cancer Biol. 5:261.[Medline]
22. Pillinger, M. H., A. S. Feoktistov, C. Capodici, B. Solitar, J. Levy, T. T. Oei, M. R. Philips. 1996. Mitogen-activated protein kinase in neutrophils and enucleate neutrophil cytoplasts: evidence for regulation of cell-cell adhesion. J. Biol. Chem. 271:12049.[Abstract/Free Full Text]
23. Capodici, C., M. H. Pillinger, G. Han, M. R. Philips, G. Weissmann. 1998. Integrin-dependent homotypic adhesion of neutrophils: arachidonic acid activates Raf-1/Mek/Erk via a 5-lipoxygenase-dependent pathway. J. Clin. Invest. 102:165.[Medline]
24. Vietor, I. P., P. Schwenger, W. Li, J. Schlessinger, J. Vilcek. 1993. Tumor necrosis factor-induced activation and increased tyrosine phosphorylation of mitogen-activated protein (MAP) kinase in human fibroblasts. J. Biol. Chem. 268:18994.[Abstract/Free Full Text]
25. Schwenger, P., E. Y. Skolnik, J. Vilcek. 1996. Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate. J. Biol. Chem. 271:8089.[Abstract/Free Full Text]
26. Poppers, D. M., P. Schwenger, J. Vilcek. 2002. Persistent tumor necrosis factor signaling in normal human fibroblasts prevents the complete resynthesis of IB-. J. Biol. Chem. 38:29587.
27. Amin, A. R., M. G. Attur, M. Pillinger, S. B. Abramson. 1999. The pleiotropic functions of aspirin: mechanisms of action. Cell. Mol. Life Sci. 56:305.[Medline]
28. Weissmann, G.. 1991. Aspirin. Sci. Am. 264:(1):84.[Medline]
29. Vane, J. R.. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231:232.[Medline]
30. Amin, A. R., P. Vyas, M. Attur, J. Leszczynska-Piziak, I. R. Patel, G. Weissmann, S. B. Abramson. 1995. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc. Natl. Acad. Sci. USA 92:7926.[Abstract/Free Full Text]
31. Kopp, E., S. Ghosh. 1994. Inhibition of NF-B by sodium salicylate and aspirin. Science 265:956.[Abstract/Free Full Text]
32. Schwenger, P., D. Alpert, E. Y. Skolnik, J. Vilcek. 1998. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IB phosphorylation and degradation. Mol. Cell. Biol. 18:78.[Abstract/Free Full Text]
33. Schwenger, P., P. Bellosta, I. Vietor, C. Basilico, E. Y. Skolkni, J. Vilcek. 1997. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 94:2869.[Abstract/Free Full Text]
34. Pillinger, M. H., C. Capodici, P. Rosenthal, N. Kheterpal, S. Hanft, G. Weissmann. 1998. Modes of action of aspirin-like drugs: salicylates inhibit Erk activation and integrin-dependent homotypic adhesion of human neutrophils. Proc. Natl. Acad. Sci. USA 95:14540.[Abstract/Free Full Text]
35. Georgescu, H. I., D. Mendelow, C. H. Evans. 1988. HIG-82: an established cell line from rabbit periarticular soft tissue, which retains the "activatable" phenotype. In Vitro Cell. Dev. Biol. 24:1015.[Medline]
36. Alvaro-Gracia, J. M., N. J. Zvaifler, G. S. Firestein. 1990. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between IFN- and TNF- on HLA-DR expression, proliferation, collagenase production, and GM-CSF production by rheumatoid arthritis synoviocytes. J. Clin. Invest. 86:1790.
37. Laemmli, U. K.. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680.[Medline]
38. Barchowsky, A., D. Frleta, M. P. Vincenti. 2000. Integration of the NF-B and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 12:1469.[Medline]
39. Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudly, A. R. Saltiel. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489.[Abstract/Free Full Text]
40. Favata, M. F., K. Y. Horiuchi, E. J. Manos, A. J. Daulerio, D. A. Stradley, W. S. Feeser, D. E. Van Dyk, W. J. Pitts, R. A. Earl, F. Hobbs, et al 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273:18623.[Abstract/Free Full Text]
41. Cuenda, A., J. Rouse, Y. N. Doza, R. Meier, P. Cohen, T. F. Gallagher, P. R. Young, J. C. Lee. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364:229.[Medline]
42. Vincenti, M. P., C. E. Brinckerhoff. 2002. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 4:157.[Medline]
43. Warner, T. D., F. Giuliano, I. Vojnovic, A. Bukasa, J. A. Mitchell, J. R. Vane. 1999. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA 96:7563.[Abstract/Free Full Text]
44. Talley, J. J., S. R. Bertenshaw, D. L. Brown, J. S. Carter, M. J. Graneto, C. M. Koboldt, J. L. Masferrer, B. H. Norman, D. J. Rogier, Jr., B. S. Zweifel, K. Seibert. 1999. 4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2). Med. Res. Rev. 19:199.[Medline]
45. Lanzo, C. A., J. Sutin, S. Rowlinson, J. Talley, L. J. Marnett. 2000. Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity. Biochemistry 39:6228.[Medline]
46. Salvatori, R., P. T. Guidon, Jr., B. E. Rapuano, R. S. Bockman. 1992. Prostaglandin E₁ inhibits collagenase gene expression in rabbit synoviocytes and human fibroblasts. Endocrinology 131:21.[Abstract/Free Full Text]
47. Suzuki, K., B. E. Rapuano, R. S. Bockman. 1997. Role of protein kinase A in collagenase-1 gene regulation by prostaglandin E₁: studies in a rabbit synoviocyte cell line, HIG-82. J. Bone Miner. Res. 12:561.[Medline]
48. Nagase, H., K. Suzuki, J. J. Enghild, G. Salvesen. 1991. Stepwise activation mechanisms of the precursors of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin). Biochim. Biophys. Acta 50:749.
49. Sun, Y., L. Wenger, C. E. Brinckerhoff, R. R. Misra, H. S. Cheung. 2002. Basic calcium phosphate crystals induce matrix metalloproteinase-1 through the Ras/mitogen-activated protein kinase/c-Fos/AP-1/metalloproteinase 1 pathway: involvement of transcription factor binding sites AP-1 and PEA-3. J. Biol. Chem. 277:1544.[Abstract/Free Full Text]
50. Menghsol, J. A., M. P. Vincenti, C. L. Coon, A. Barchowsky, C. E. Brinckerhoff. 2000. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor B: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 43:801.[Medline]
51. Cook, S. J., F. McCormick. 1993. Inhibition by cAMP of ras-dependent activation of Raf. Science 262:1069.[Abstract/Free Full Text]
52. Wu, J., P. Dent, T. Jelinek, A. Wolfman, M. J. Weber, T. W. Sturgill. 1993. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. Science 262:1065.[Abstract/Free Full Text]
53. Dumaz, N., R. Marais. 2003. PKA blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J. Biol. Chem. 278:29819.[Abstract/Free Full Text]
54. Pillinger, M. H., M. R. Philips, A. Feoktistov, G. Weissmann. 1995. Crosstalk in signal transduction via EP receptors: prostaglandin E₁ inhibits chemoattractant-induced mitogen-activated protein kinase activity in human neutrophils. B. Samuelsson, Jr., ed. In Advances in Prostaglandin, Thromboxane, and Leukotriene Reserach Vol. 23:311. Raven Press, New York.
55. Pillinger, M. H., C. Capodici, G. Han, G. Weissmann. 1997. Inflammation and anti-inflammation: gating of cell-cell adhesion at the level of mitogen-activated protein kinases. Ann. NY Acad. Sci. 832:1.[Medline]
56. Dayer, J. M., S. M. Krane, R. G. Russell, D. R. Robinson. 1976. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc. Natl. Acad. Sci. USA 73:945.[Abstract/Free Full Text]
57. He, W., J. P. Pelletier, J. Martel-Pelletier, S. Laufer, J. A. DiBattista. 2002. Synthesis of interleukin-1, tumor necrosis factor-, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J. Rheum. 29:546.[Abstract/Free Full Text]
58. DiBattista, J. A., J. Martel-Pelletier, N. Fujimoto, K. Obata, M. Zafarullah, J.-P. Pelletier. 1994. Prostaglandins E₂ and E₁ inhibit cytokine-induced metalloproteinase expression in human synovial fibroblasts. Lab. Invest. 71:270.[Medline]
59. DiBattista, J. A., M. Martel-Pelletier, N. Morin, F. C. Jolicoeur, J. P. Pelletier. 1994. Transcriptional regulation of plasminogen activator inhibitor-1 expression in human synovial fibroblasts by prostaglandin E₂: mediation by protein kinase A and role of interleukin-1. Mol. Cell. Endocrinol. 103:139.[Medline]
60. Zurier, R. B., F. Quagliata. 1971. Effect of prostaglandin E₁ on adjuvant arthritis. Nature 234:304.[Medline]
61. Zurier, R. B., I. Damjanov, D. M. Sayadoff, N. F. Rothfield. 1977. Prostaglandin E₁ treatment of NZB/NZW F₁ hybrid mice. Arthritis Rheum. 20:1449.[Medline]
62. Pelletier, J.-P., J. C. Fernandes, J. Brunet, F. Moldovan, D. Schrier, C. Flory, J. Martel-Pelletier. 2003. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 48:1582.[Medline]

This article has been cited by other articles:

				E. Kunisch, A. Jansen, F. Kojima, I. Loffler, M. Kapoor, S. Kawai, I. Rubio, L. J. Crofford, and R. W. Kinne Prostaglandin E2 Differentially Modulates Proinflammatory/Prodestructive Effects of TNF-{alpha} on Synovial Fibroblasts via Specific E Prostanoid Receptors/cAMP J. Immunol., July 15, 2009; 183(2): 1328 - 1336. [Abstract] [Full Text] [PDF]

				L. Rand, J. A. Green, L. Saraiva, J. S. Friedland, and P. T. G. Elkington Matrix Metalloproteinase-1 Is Regulated in Tuberculosis by a p38 MAPK-Dependent, p-Aminosalicylic Acid-Sensitive Signaling Cascade J. Immunol., May 1, 2009; 182(9): 5865 - 5872. [Abstract] [Full Text] [PDF]

				E S Molloy, M P Morgan, G A Doherty, B McDonnell, J O'Byrne, D J Fitzgerald, and G M McCarthy Mechanism of basic calcium phosphate crystal-stimulated matrix metalloproteinase-13 expression by osteoarthritic synovial fibroblasts: inhibition by prostaglandin E2 Ann Rheum Dis, December 1, 2008; 67(12): 1773 - 1779. [Abstract] [Full Text] [PDF]

				M. Attur, H. E. Al-Mussawir, J. Patel, A. Kitay, M. Dave, G. Palmer, M. H. Pillinger, and S. B. Abramson Prostaglandin E2 Exerts Catabolic Effects in Osteoarthritis Cartilage: Evidence for Signaling via the EP4 Receptor J. Immunol., October 1, 2008; 181(7): 5082 - 5088. [Abstract] [Full Text] [PDF]

				C. E. Tagoe, N. Marjanovic, J. Y. Park, E. S. Chan, A. M. Abeles, M. Attur, S. B. Abramson, and M. H. Pillinger Annexin-1 Mediates TNF-{alpha}-Stimulated Matrix Metalloproteinase Secretion from Rheumatoid Arthritis Synovial Fibroblasts J. Immunol., August 15, 2008; 181(4): 2813 - 2820. [Abstract] [Full Text] [PDF]

				M. A. Alvarez-Soria, G. Herrero-Beaumont, O. Sanchez-Pernaute, M. Bellido, and R. Largo Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast--comparison to its effects on osteoarthritic chondrocytes Rheumatology, May 1, 2008; 47(5): 627 - 633. [Abstract] [Full Text] [PDF]

				M. Minami, K. Shimizu, Y. Okamoto, E. Folco, M.-L. Ilasaca, M. W. Feinberg, M. Aikawa, and P. Libby Prostaglandin E Receptor Type 4-associated Protein Interacts Directly with NF-{kappa}B1 and Attenuates Macrophage Activation J. Biol. Chem., April 11, 2008; 283(15): 9692 - 9703. [Abstract] [Full Text] [PDF]

				T. Thalhamer, M. A. McGrath, and M. M. Harnett MAPKs and their relevance to arthritis and inflammation Rheumatology, April 1, 2008; 47(4): 409 - 414. [Abstract] [Full Text] [PDF]

				P. T. Elkington, J. A. Green, J. E. Emerson, L. D. Lopez-Pascua, J. J. Boyle, C. M. O'Kane, and J. S. Friedland Synergistic Up-Regulation of Epithelial Cell Matrix Metalloproteinase-9 Secretion in Tuberculosis Am. J. Respir. Cell Mol. Biol., October 1, 2007; 37(4): 431 - 437. [Abstract] [Full Text] [PDF]

				M. H. Pillinger, N. Marjanovic, S.-Y. Kim, Y.-C. Lee, J. U. Scher, J. Roper, A. M. Abeles, P. I. Izmirly, M. Axelrod, M. Y. Pillinger, et al. Helicobacter pylori Stimulates Gastric Epithelial Cell MMP-1 Secretion via CagA-dependent and -independent ERK Activation J. Biol. Chem., June 29, 2007; 282(26): 18722 - 18731. [Abstract] [Full Text] [PDF]

				K. S. Mix, M. G. Attur, H. Al-Mussawir, S. B. Abramson, C. E. Brinckerhoff, and E. P. Murphy Transcriptional Repression of Matrix Metalloproteinase Gene Expression by the Orphan Nuclear Receptor NURR1 in Cartilage J. Biol. Chem., March 30, 2007; 282(13): 9492 - 9504. [Abstract] [Full Text] [PDF]

				T. Maeda, M. Hirayama, D. Kobayashi, K. Miyazawa, and I. Tamai Mechanism of the Regulation of Organic Cation/Carnitine Transporter 1 (SLC22A4) by Rheumatoid Arthritis-Associated Transcriptional Factor RUNX1 and Inflammatory Cytokines Drug Metab. Dispos., March 1, 2007; 35(3): 394 - 401. [Abstract] [Full Text] [PDF]

				A. Alfranca, M. A. Iniguez, M. Fresno, and J. M. Redondo Prostanoid signal transduction and gene expression in the endothelium: Role in cardiovascular diseases Cardiovasc Res, June 1, 2006; 70(3): 446 - 456. [Abstract] [Full Text] [PDF]

				P. F. Gomez, M. H. Pillinger, M. Attur, N. Marjanovic, M. Dave, J. Park, C. O. Bingham III, H. Al-Mussawir, and S. B. Abramson Resolution of Inflammation: Prostaglandin E2 Dissociates Nuclear Trafficking of Individual NF-{kappa}B Subunits (p65, p50) in Stimulated Rheumatoid Synovial Fibroblasts J. Immunol., November 15, 2005; 175(10): 6924 - 6930. [Abstract] [Full Text] [PDF]

				P. T. G. Elkington, J. E. Emerson, L. D. C. Lopez-Pascua, C. M. O'Kane, D. E. Horncastle, J. J. Boyle, and J. S. Friedland Mycobacterium tuberculosis Up-Regulates Matrix Metalloproteinase-1 Secretion from Human Airway Epithelial Cells via a p38 MAPK Switch J. Immunol., October 15, 2005; 175(8): 5333 - 5340. [Abstract] [Full Text] [PDF]

				M. H. Pillinger, N. Marjanovic, S.-Y. Kim, J. U. Scher, P. Izmirly, S. Tolani, V. Dinsell, Y.-C. Lee, M. J. Blaser, and S. B. Abramson Matrix Metalloproteinase Secretion by Gastric Epithelial Cells Is Regulated by E Prostaglandins and MAPKs J. Biol. Chem., March 18, 2005; 280(11): 9973 - 9979. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pillinger, M. H. Articles by Abramson, S. B. Search for Related Content PubMed PubMed Citation Articles by Pillinger, M. H. Articles by Abramson, S. B.